Anika Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Anika Therapeutics

01/11/2023 02:31

* Anika Therapeutics Inc  ANIK.OQ   ANIK.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Bedford Massachusetts-based  company is expected to
report 
a 5.0% decrease in revenue to $38.266 million from $40.26
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Anika Therapeutics
Inc is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $24​, above​ its last closing price
of $19.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.27       -0.27      -0.19     Beat    29.6
 Mar. 31 2023  -0.33       -0.30      -0.47     Missed  -56.7
 Dec. 31 2022  -0.25       -0.24      -0.34     Missed  -41.7​
 Sep. 30 2022  -0.25       -0.25      -0.15     Beat    40
 ​​Jun.        -0.21       -0.23      -0.20     Beat    11.8
 30 2022                                                
 Mar. 31 2022  -0.37       -0.36      -0.20     Beat    45.2​
 Dec. 31 2021  -0.29       -0.25      -0.40     Missed  -58.4
 Sep. 30 2021  -0.21       -0.21      0.04      Beat    119
 This summary was machine generated November 1 at 02:30 GMT.  All
figures in US dollars  unless otherwise stated